The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions.

IF 2.4 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Medicina-Lithuania Pub Date : 2025-03-17 DOI:10.3390/medicina61030518

Young-Bin Cho, Kyoung-Sik Park

引用次数: 0

Abstract

Gene mutations in PIK3CA, the catalytic subunit of phosphoinositide 3-kinases, are significantly associated with prognosis in breast cancer. This association suggests that breast cancer patients with PIK3CA mutations should receive PIK3CA mutant-specific treatment. This review aimed to investigate novel treatments for PIK3CA-mutant breast cancer. This study investigated the effects of PIK3CA mutations in breast cancer with respect to gene ontology and the PI3K/AKT/mTOR pathway. Subsequently, we comprehensively examined all clinical trials that targeted breast cancer patients with PIK3CA mutations. Finally, this review explored the potential of a new treatment for noncoding RNA.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicina-Lithuania 医学-医学：内科

CiteScore

3.30

自引率

3.80%

发文量

1578

审稿时长

25.04 days

期刊介绍： The journal’s main focus is on reviews as well as clinical and experimental investigations. The journal aims to advance knowledge related to problems in medicine in developing countries as well as developed economies, to disseminate research on global health, and to promote and foster prevention and treatment of diseases worldwide. MEDICINA publications cater to clinicians, diagnosticians and researchers, and serve as a forum to discuss the current status of health-related matters and their impact on a global and local scale.